Melanoma · 4 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and nab-Paclitaxel (CnP) Variant #01 | — | R 41 178 | 21d | ~5.7 mo | ~13.9 mo | ~4 | ~R 164 713 PFS proxy · indirect | 11 |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | 4.1 mo | — | 12 | R 12 296 PFS proxy | 1 |
Lifileucel and IL-2 Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Toripalimab monotherapy Variant #01 Partial | — | — | 14d | — | — | ~11 | — | — |
4 of 4 regimens shown